B+
Bull case
20%
Probability
Target price
$101.00
+11.5% vs current
TRNS
TranscatDNasdaq / Capital Goods
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$83.00
-8.3% vs current
B-
Bear case
25%
Probability
Target price
$58.00
-36.0% vs current
AI sentiment snapshot
Latest data as of 2026-05-18
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+37.3
Score
AI commentary
Primary-source headline flow is constructive but narrow: the company confirmed a CEO transition, a Latin America acquisition, and continued service growth in the latest quarter. That said, analyst coverage is sparse, social context is unavailable, and the filing trail still shows earnings conversion pressure and leverage to monitor, so this remains a cautious hold rather than a clear re-rating setup.
RankAlpha Sentiment Codex - 2026-05-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30eventCEO handoff resets execution barMedium impact
Jaime Irick is now the CEO, Rudow remains a senior advisor through March 2027, and the company said the resignation was not due to any disagreement; the near-term impact is mainly an execution and integration test rather than an immediate operating reset [#8-K-2026-03-09].
2026-08-15catalystRevenue growth still needs cleaner earnings conversionMedium impact
FY26 nine-month revenue growth has outpaced GAAP profit conversion so far, with service revenue up to $155.6 million and total revenue up to $242.6 million but service operating income and net income still pressured by amortization, transition costs, and interest expense [#10-Q-2026-02-03].
2026-12-31catalystLatin America footprint can widen the service networkHigh impact
The SCM Metrology deal gives Transcat its first operating presence in Latin America and adds local calibration capacity with potential cross-sell into multinational med-tech and life-science accounts; the upside case depends on integration quality and whether the new footprint translates into recurring service and distribution revenue.
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-18 • Updated nightlySource: Internal modelMethodology